Sculpting humoral immunity through dengue vaccination to enhance protective immunity

Frontiers in Immunology

Volumn 3, Issue NOV, 2012, Pages

  Crill, Wayne D ^a   Hughes, Holly R ^a,b   Trainor, Nicole B ^a   Davis, Brent S ^a   Whitney, Matt T ^a   Chang, Gwong Jen J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

Antibody dependent enhancement; Dengue; Dengue hemorrhagic fever; Dengue vaccines; DNA vaccines; Immune refocusing; Original antigenic sin; Vaccine safety

Indexed keywords

EID: 84874212395     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00334     Document Type: Article

References (84)

1. Balsitis, S. J., Williams, K. L., Lachica, R., Flores, D., Kyle, J. L., Mehlhop, E., et al. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by fc modification. PLoS Pathog. 6, e1000790. doi: 10.1371/journal.ppat.1000790
2. Beltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T., et al. (2010). The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283.
3. Brehm, M. A., Pinto, A. K., Daniels, K. A., Schneck, J. P., Welsh, R. M., and Selin, L. K. (2002). T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat. Immunol. 3, 627-634.
4. Chang, G. J., Davis, B. S., Hunt, A. R., Holmes, D. A., and Kuno, G. (2001). Flavivirus DNA vaccines: current status and potential. Ann. N. Y.Acad. Sci. 951, 272-285.
5. Chang, G. J., Davis, B. S., String-field, C., and Lutz, C. (2007). Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection. Vaccine 25, 2325-2330.
6. Chang, G. J., Hunt, A. R., Holmes, D. A., Springfield, T., Chiueh, T. S., Roehrig, J. T., et al. (2003). Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306, 170-180.
7. Chen, L., Ewing, D., Subramanian, H., Block, K., Rayner, J., Alterson, K. D., et al. (2007). A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J. Virol. 81, 11634-11639.
8. Chiou, S. S., Fan, Y. C., Crill, W. D., Chang, R. Y., and Chang, G. J. (2012). Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein. J. Gen. Virol. 93, 1185-1192.
9. Cockburn, J. J., Navarro Sanchez, M. E., Fretes, N., Urvoas, A., Staropoli, I., Kikuti, C. M., et al. (2012). Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 8, 303-314.
10. Crill, W D., and Chang, G. J. (2004). Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78, 13975-13986.
11. Crill, W. D., Hughes, H. R., Delorey, M. J., and Chang, G. J. (2009). Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4, e4991. doi: 10.1371/journal.pone.0004991
12. Dale, C. J., Thomson, S., De Rose, R., Ranasinghe, C., Medveczky, C. J., Pamungkas, J., et al. (2006). Prime-boost strategies in DNA vaccines. Methods Mol. Med. 127, 171-197.
13. Davis, B. S., Chang, G. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., et al. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75, 4040-4047.
14. de Alwis, R., Beltramello, M., Messer, W. B., Sukupolvi-Petty, S., Wahala, W. M., Kraus, A., et al. (2011). In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5, e1 188. doi: 10.1371/jour-nal.pntd.0001188
15. de Alwis R., Smith, S. A., Olivarez, N. P., Messer, W. B., Huynh, J. P., Wahala, W. M., et al. (2012). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U.S.A. 109, 7439-7444.
16. Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., et al. (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748.
17. Ding, H., Tsai, C., Gutierrez, R. A., Zhou, F., Buchy, P., Deubel, V., and Zhou, P. (2011). Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAIH5N1 virus. PLoS ONE 6, e16563. doi: 10.1371/jour-nal.pone.0016563
18. Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., Limpitikul, W., Tangthawornchaikul, N., Malasit, P., et al. (2010). Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. U.S.A. 107, 16922-16927.
19. Durbin, A. P., and Whitehead, S. S. (2009). Dengue vaccine candidates in development. Curr. Top. Microbiol. Immunol. 338, 129-143.
20. Durbin, A. P., and Whitehead, S. S. (2011). Next-generation dengue vaccines: novel strategies currently under development. Viruses 3, 1800-1814.
21. Francis, T. Jr. (1953). Influenza: the new acquayantance. Ann. Intern. Med. 39, 203-221.
22. Friberg, H., Burns, L., Woda, M., Kalayanarooj, S., Endy, T. P., Stephens, H. A., et al. (2011). Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol. CellBiol. 89, 122-129.
23. Goncalvez, A. P., Engle, R. E., St Claire, M., Purcell, R. H., and Lai, C. J. (2007). Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U.S.A. 104, 9422-9427.
24. Gromowski, G. D., and Barrett, A. D. (2007). Characterization of an anti-genic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360.
25. Gromowski, G. D., Barrett, N. D., and Barrett, A. D. (2008). Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82, 8828-8837.
26. Gubler, D. J. (2002). The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 33, 330-342.
27. Gubler, D. J. (2006). Dengue/dengue haemorrhagic fever: history and current status. Novartis Found. Symp. 277, 3-16; discussion 16-22, 71-13, 251-253.
28. Guenaga, J., Dosenovic, P., Ofek, G., Baker, D., Schief, W R., Kwong, P. D., et al. (2011). Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6, e16074. doi: 10.1371/journal.pone.0016074
29. Guy, B., Barban, V., Mantel, N., Aguirre, M., Gulia, S., Pontvianne, J., et al. (2009). Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80, 302-311.
30. Guy, B., Barrere, B., Malinowski, C., Saville, M., Teyssou, R., and Lang, J. (2011). From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29, 7229-7241.
31. Guy, B., Saville, M., and Lang, J. (2010). Development of Sanofi Pasteur tetravalent dengue vaccine. Hum. Vaccin. 6, 1-10.
32. Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., et al. (2010). Dengue: a continuing global threat. Nat. Rev. Microbiol. 8, S7-S16.
33. Halstead, S. B. (1989). Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a patho-genetic cascade. Rev. Infect. Dis. 11(Suppl. 4), S830-S839.
34. Hawkes, R. A. (1964). Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42, 465-482.
35. Heinz, F. X., and Stiasny, K. (2012). Flaviviruses and flavivirus vaccines. Vaccine 30, 4301-4306.
36. Henchal, E. A., Mccown, J. M., Burke, D. S., Seguin, M. C., and Brandt, W. E. (1985). Epitopic analysis of anti-genic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34, 162-169.
37. Hughes, H. R., Crill, W D., and Chang, G. J. (2012). Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J. 9, 115.
38. Hughes, H. R., Crill, W D., Davis, B. S., and Chang, G. J. (2012). A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology 424, 129-137.
39. Kuno, G. (2003). Serodiagnosis of fla-viviral infections and vaccinations in humans. Adv. Virus Res. 61, 3-65.
40. Lai, C. Y., Tsai, W Y., Lin, S. R., Kao, C. L., Hu, H. P., King, C. C., et al. (2008). Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82, 6631-6643.
41. Laylor, R., Porakishvili, N., De Souza, J. B., Playfair, J. H., Delves, P. J., and Lund, T. (1999). DNA vaccination favours memory rather than effector B cell responses. Clin. Exp. Immunol. 117, 106-112.
42. Libraty D. H., Endy, T. P., Houng, H. S., Green, S., Kalayanarooj, S., Suntayakorn, S., et al. (2002). Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.J. Infect. Dis. 185, 1213-1221.
43. Lin, S. R., Zou, G., Hsieh, S. C., Qing, M., Tsai, W. Y., Shi, P. Y., et al. (2011). The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry. J. Virol. 85, 5159-5171.
44. Mackenzie, J. S., Gubler, D. J., and Petersen, L. R. (2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-S109.
45. Martin, J. E., Pierson, T. C., Hubka, S., Rucker, S., Gordon, I. J., Enama, M. E., et al. (2007). A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196, 1732-1740.
46. Mathew, A., andRothman, A. L. (2008). Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225, 300-313.
47. Miller, N. (2010). Recent progress in dengue vaccine research and development. Curr. Opin. Mol. Ther. 12, 31-38.
48. Modis, Y., Ogata, S., Clements, D., and Harrison, S. C. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100, 6986-6991.
49. Morens, D. M. (1994). Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19, 500-512.
50. Morrison, D., Legg, T. J., Billings, C. W., Forrat, R., Yoksan, S., and Lang, J. (2010). A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201, 370-377.
51. Murphy, B. R., and Whitehead, S. S. (2011). Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29, 587-619.
52. Nara, P. L., Tobin, G. J., Chaudhuri, A. R., Trujillo, J. D., Lin, G., Cho, M. W., et al. (2011). How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol. 8, e1000571. doi: 10.1371/jour-nal.pbio.1000571
53. Ndifon, W., Wingreen, N. S., and Levin, S. A. (2009). Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc. Natl. Acad. Sci. U.S.A. 106, 8701-8706.
54. Petersen, L. R., and Roehrig, J. T. (2007). Flavivirus DNA vaccines-good science, uncertain future. J. Infect. Dis. 196, 1721-1723.
55. Pierson, T. C., Fremont, D. H., Kuhn, R. J., and Diamond, M. S. (2008). Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4, 229-238.
56. Rodenhuis-Zybert, I. A., Van Der Schaar, H. M., Da Silva Voorham, J. M., Van Der Ende-Metselaar, H., Lei, H. Y., Wilschut, J., et al. (2010). Immature dengue virus: a veiled pathogen? PLoS Pathog. 6, e1000718. doi: 10.1371/journal.ppat. 1000718
57. Roehrig, J. T., Bolin, R. A., and Kelly, R. G. (1998). Monoclonal antibody mapping of the envelope glycopro-tein of the dengue 2 virus, Jamaica. Virology 246, 317-328.
58. Roehrig, J. T., Risi, P. A., Brubaker, J. R., Hunt, A. R., Beaty, B. J., Trent, D. W., et al. (1994). T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 198, 31-38.
59. Rothman, A. L. (2004). Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946-951.
60. Sabin, A. B. (1952). Research on dengue during WWII. Am. J. Trop. Med. Hyg. 1, 30-50.
61. Schijns, V. E., Haagmans, B. L., Rijke, E. O., Huang, S., Aguet, M., and Horzinek, M. C. (1994). IFN-gamma receptor-deficient mice generate antiviral Th1-characteristic cytokine profiles but altered antibody responses. J. Immunol. 153, 2029-2037.
62. Schmitz, J., Roehrig, J., Barrett, A., and Hombach, J. (2011). Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29, 7276-7284.
63. Shresta, S., Sharar, K. L., Prigozhin, D. M., Beatty, P. R., and Harris, E. (2006). Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80, 10208-10217.
64. Simmons, M., Burgess, T., Lynch, J., and Putnak, R. (2010). Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396, 280-288.
65. Sin Leo, Y., Wilder-Smith, A., Archuleta, S., Shek, L., Chong, C. Y., Nam Leong, H., et al. (2012). Immunogenicity and safety of recombinant tetrava-lent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum. Vaccin. Immunother. 8. [Epub ahead of print].
66. Stiasny, K., Kiermayr, S., Holzmann, H., and Heinz, F. X. (2006). Cryptic properties of a cluster of dominant flavivirus cross-reactive anti-genic sites. J. Virol. 80, 9557-9568.
67. Sukupolvi-Petty, S., Austin, S. K., Purtha, W E., Oliphant, T., Nybakken, G. E., Schlesinger, J. J., et al. (2007). Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81, 12816-12826.
68. Sun, W., Cunningham, D., Wasserman, S. S., Perry, J., Putnak, J. R., Eckels, K. H., et al. (2009). Phase 2 clinical trial of three formulations of tetrava-lent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin. 5, 33-40.
69. Thomas, S., Redfern, J. B., Lidbury, B. A., and Mahalingam, S. (2006). Antibody-dependent enhancement and vaccine development. Expert Rev. Vaccines 5, 409-412.
70. Thomas, S. J. (2011). The necessity and quandaries of dengue vaccine development. J. Infect. Dis. 203, 299-303.
71. Tobin, G. J., Trujillo, J. D., Bushnell, R. V., Lin, G., Chaudhuri, A. R., Long, J., et al. (2008). Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26, 6189-6199.
72. Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., Suntayakorn, S., et al. (2000). Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2-9.
73. Wahala, W M., Huang, C., Butrapet, S., White, L. J., and De Silva, A. M. (2012). Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J. Virol. 86, 4019-4023.
74. Walker, L. M., and Burton, D. R. (2010). Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358-366.
75. Wei, C. J., Boyington, J. C., Mctam-ney, P. M., Kong, W. P., Pearce, M. B., Xu, L., et al. (2010). Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064.
76. Welsh, R. M., and Fujinami, R. S. (2007). Pathogenic epitopes, heterol-ogous immunity and vaccine design. Nat. Rev. Microbiol. 5, 555-563.
77. Welsh, R.M., andSelin, L. K. (2002). No one is naive: the significance of het-erologous T-cell immunity. Nat. Rev. Immunol. 2, 417-426.
78. Welsh, R. M., Selin, L. K., and Szomolanyi-Tsuda, E. (2004). Immunological memory to viral infections. Annu. Rev. Immunol. 22, 711-743.
79. Williams, K. L., Zompi, S., Beatty, P. R., and Harris, E. (2009). A mouse model for studying dengue virus pathogenesis and immune response. Ann. N. Y. Acad. Sci. 1171(Suppl. 1), E12-E23.
80. Yauch, L. E., Prestwood, T. R., May, M. M., Morar, M. M., Zellweger, R. M., Peters, B., et al. (2010). CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185, 5405-5416.
81. Yauch, L. E., Zellweger, R. M., Kotturi, M. F., Qutubuddin, A., Sidney, J., Peters, B., et al. (2009). A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182, 4865-4873.
82. Zellweger, R. M., Prestwood, T. R., and Shresta, S. (2010). Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7, 128-139.
83. Zhang, W., Chipman, P. R., Corver, J., Johnson, P. R., Zhang, Y., Mukhopadhyay, S., et al. (2003). Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10, 907-912.
84. Zompi, S., Santich, B. H., Beatty, P. R., and Harris, E. (2012). Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J. Immunol. 188, 404-416.